Novo Nordisk Jorgensen on U.S. Obesity Drugs Market

Lars Jorgensen, CEO of Novo Nordisk, discusses the company's strong business momentum driven by innovative GLP-1 products in diabetes and obesity care. He addresses the challenges of supply chain bottlenecks for the obesity drug Wegovy and outlines the eligibility criteria for its use. Jorgensen also talks about the US market's significance, drug pricing debates, and the company's support programs for patients. He concludes with insights on margin expansion and future growth strategies, emphasizing the shift from insulin to higher-margin GLP-1 products.

What challenges is Novo Nordisk facing in the supply chain for their new obesity drug?

What is the company's stance on drug pricing and regulatory concerns in the US market?